AI Leaders Urge Mandatory Screening of Synthetic DNA

A coalition of more than 80 signatories, organized by the Foundation for American Innovation and the Institute for Progress, published an open letter on June 4, 2026 (hosted at screendna.org) calling for mandatory screening and recordkeeping of synthetic nucleic acid orders. Signatories include OpenAI's Sam Altman, Google DeepMind's Demis Hassabis, Anthropic's Dario Amodei, and Microsoft AI's Mustafa Suleyman, alongside 2024 Nobel laureates in chemistry Demis Hassabis and David Baker, and executives from DNA-synthesis manufacturers Twist Bioscience and Ansa Biotechnologies (FAI; Vox; PCMag). The letter states that AI could erode the "knowledge barriers which have historically prevented bad actors from obtaining biological weapons." Chemical & Engineering News reports the bipartisan Biosecurity Modernization and Innovation Act of 2026, introduced by Senators Tom Cotton and Amy Klobuchar, would require synthetic-DNA sellers to screen orders and verify customers.

The letter calls for screening synthesis orders against lists of "sequences of concern," verifying customer legitimacy, and keeping records to support investigations. Many commercial DNA providers already screen orders voluntarily under standards set by the International Gene Synthesis Consortium (IGSC), founded in 2009 (FAI; Vox). A peer-reviewed review in PMC on AI-biotech convergence notes that machine learning is accelerating both the capability and the governance complexity of molecular-biology design tools.

Mandating screening follows a conventional policy pattern for dual-use technologies, similar to regimes already used in the chemical and nuclear domains; it would shift a currently voluntary, fragmented set of provider checks toward a uniform compliance baseline, improving traceability but raising operational, privacy, and international-enforcement questions. The fact that competing AI lab CEOs and Nobel laureates signed the same letter raises the story's political salience and may accelerate momentum behind the Cotton-Klobuchar bill in Congress.

Mandated checks at scale tend to create friction in legitimate research supply chains, which typically drives demand for secure, privacy-preserving customer-verification workflows and automated sequence-vetting tools that balance false positives against operational throughput.

• •Whether Congress advances or amends the Cotton-Klobuchar bill and how agencies define the regulatory "list of sequences of concern."
• •Whether the IGSC's voluntary screening standards get codified into law or supplemented with new compliance tooling.
• •Proposals for privacy-preserving verification and automated sequence-vetting tools from synthesis providers.